Skip to main content

Find Clinical Trials

Home
Conditions
Recurrent Melanoma

Clinical trial condition

Recurrent Melanoma

Explore clinical trials studying Recurrent Melanoma. Study availability and eligibility vary by location and protocol.

83 public trials 2 recruiting studies

Refine in advanced search Browse all conditions

Recurrent Melanoma trial results

Completed

Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors

NCT01522820

Conditions: Adenocarcinoma, Adnexal Diseases, Anaplastic Astrocytoma, +137 more
Locations: Roswell Park Cancer Institute Buffalo, New York, United States

View Trial Details

Completed

Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma

NCT00026221

Conditions: Melanoma, Neoplasms, Neoplasms by Histologic Type, +11 more
Locations: University of Cincinnati Cincinnati, Ohio, United States

Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States

View Trial Details

Completed

Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

NCT00110019

Conditions: Melanoma, Mucosal Melanoma, Neoplasms, +15 more
Locations: University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States

Mercy Hospital Fort Smith Fort Smith, Arkansas, United States

University of Arkansas for Medical Sciences Little Rock, Arkansas, United States

Providence Saint Joseph Medical Center/Disney Family Cancer Center Burbank, California, United States

View all 219 locations

View Trial Details

Completed

Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma

NCT00085306

Conditions: Eye Diseases, Eye Neoplasms, Melanoma, +16 more
Locations: Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland, Ohio, United States

View Trial Details

Completed

MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma

NCT00866177

Conditions: Melanoma, Neoplasms, Neoplasms by Histologic Type, +12 more
Locations: Memorial Sloan-Kettering Cancer Center New York, United States

View Trial Details

Completed

Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery

NCT01989559

Conditions: Melanoma, Neoplasms, Neoplasms by Histologic Type, +19 more
Locations: Providence Portland Medical Center Portland, Oregon, United States

View Trial Details

Completed

Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors

NCT01131234

Conditions: Adenocarcinoma, Adnexal Diseases, Adult Anaplastic Astrocytoma, +120 more
Locations: Juravinski Cancer Centre at Hamilton Health Sciences Hamilton, Ontario, Canada

University Health Network-Princess Margaret Hospital Toronto, Ontario, Canada

View Trial Details

Completed

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

NCT00470470

Conditions: Acral Lentiginous Malignant Melanoma, Melanoma, Neoplasms, +15 more
Locations: University of California at Los Angeles (UCLA ) Los Angeles, California, United States

Mount Sinai Medical Center CCOP Miami Beach, Florida, United States

Good Samaritan Medical Center West Palm Beach, Florida, United States

Palm Beach Cancer Institute-Main Office West Palm Beach, Florida, United States

View Trial Details

Completed

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

NCT00085189

Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Extraocular Extension Melanoma, +31 more
Locations: University of Southern California Los Angeles, California, United States

View Trial Details

Completed

Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

NCT00669019

Conditions: Melanoma, Neoplasms, Neoplasms by Histologic Type, +14 more
Locations: University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States

View Trial Details